Acorai is a technology company.
Acorai is a technology company.
Acorai has raised $5.0M across 1 funding round.
Acorai has raised $5.0M in total across 1 funding round.
Acorai is a Swedish health tech startup founded in 2019 that develops the Acorai Heart Monitor, a non-invasive handheld device for estimating intracardiac pressures in heart failure patients using seismic, acoustic, visual, and ECG sensors combined with machine learning.[1][2][5] It primarily serves healthcare professionals in hospitals to improve heart failure management for over 60 million patients worldwide by enabling frequent, trend-based monitoring without invasive procedures like catheterization, which only reaches about 10% of patients.[1][2] The company has raised $23.8M total, including a recent $4.5M round six months ago, and has demonstrated clinical accuracy matching gold standards in a 200-patient feasibility study, positioning it for commercialization with low regulatory risk.[1][3]
Acorai was co-founded in 2019 in Helsingborg, Sweden, by Filip Peters (CEO) and Jakob Gelberg (CTO), who drew inspiration from non-medical industries like oil and gas for non-invasive pressure sensing via seismic and acoustic technologies, adapting them for cardiac diagnostics.[2][4] The initial concept targeted remote at-home monitoring for preventive care, but pivoted to in-hospital use after feedback from cardiologists and nurses highlighted unmet needs in managing admitted heart failure patients, offering a superior value proposition.[2] Early traction came from a 200-patient feasibility study validating accuracy against invasive methods, alongside partnerships with top institutions like Cedars-Sinai, Mayo Clinic, and Royal Brompton Hospital.[1][5]
Acorai rides the wave of AI-driven, non-invasive diagnostics in medtech, addressing the global heart failure crisis affecting 64 million patients amid rising hospitalizations and readmissions.[1][2] Timing aligns with post-pandemic demands for scalable hospital tools that reduce invasive procedures (used in only 10% of cases) and enable personalized treatment, fueled by machine learning advancements and data from leading hospitals.[2][5] Market tailwinds include aging populations, healthcare cost pressures, and regulatory fast-tracks for low-risk devices; competitors like Bodyport (scale-based monitoring) and Datos Health (AI workflows) focus on remote or broader RPM, but Acorai's in-hospital precision via novel sensor stacks carves a niche in acute care.[1] It influences the ecosystem by partnering with top U.S./U.K. centers, potentially setting standards for multi-sensor cardiac tech and lowering barriers for similar innovations.[5]
Acorai's momentum—oversubscribed seed, clinical wins, and elite partnerships—positions it for U.S. market entry and broader adoption in heart failure care, with next steps likely including FDA clearance, expanded trials, and Series A funding.[1][2][3] Trends like AI-sensor integration and value-based care will propel growth, evolving its influence from hospital tool to ecosystem platform via data partnerships. As non-invasive monitoring disrupts invasive norms, Acorai could redefine scalable heart failure management, echoing its origins in overlooked in-hospital needs.[2][5]
Acorai has raised $5.0M in total across 1 funding round.
Acorai has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $5.0M Seed |